Will Heyburn
Analyst · Deutsche Bank. Your line is now live
Thank you, Rob. Before we dive in, I'd like to reemphasize our great progress in both growing and diversifying our business. Where Blade was once highly-concentrated in New York City, we now have an even larger passenger urban air mobility business in Vancouver. Our MediMobility organ transport and jet businesses operate coast-to-coast, and Blade is now the largest dedicated transporter of human organs for transplant in the United States. This diversification has served us incredibly well during a volatile time for the consumer travel industry. Additionally, given common aircraft usage across all of our business lines, we have significantly strengthened the Blade value proposition with our third-party operators. The combined volumes of our growing retail and medical businesses are already leading to improve the aircraft availability and pricing, paving the way for improved economics. As Rob mentioned earlier, our 208% revenue growth in the December 2021 quarter versus the comparable 2020 period was well ahead of our expectations. I'll walk through a few highlights. In Short Distance, revenues were up 191% to $6.2 million in the December 2021 quarter versus $2.1 million in the comparable 2020 period. Our commuter business continued to benefit from strong off season demand. And what is seasonally the second slowest quarter for short business. Our reintroduction of Blade Airport service and acquisition of Helijet passenger routes, which we completed on November 30th, also contributed to the positive year-over-year comparison. Turning to MediMobility Organ Transport and Jet, revenues increased 227% this quarter to $18 million versus $5.5 million in the comparable 2020 period. Growth was driven by our acquisition of Trinity, the addition of new hospital and jet charter clients, as well as growth in trip volume within Blade 's legacy accounts. We worked quickly to integrate Trinity and have already won several new accounts for the combined Trinity Blade team. We're particularly pleased to be supporting our longstanding partner, Mount Sinai Hospital as they expand their transplant institute to add a lung program this year. Turning to our flight costs. Flight Margin decreased this quarter to 16% versus 20% in the comparable 2020 period. The decline was driven primarily by the recent relaunch of BLADE Airport service, which, as expected, during any new service ramp, was operating below breakeven during the 2021 period. Absent BLADE Airport, flight margin would have been approximately 18% in the period. Let's turn now to our general and administrative expenses. G&A increased $9 million in the December 2021 quarter to $12.3 million from $3.4 million in the comparable 2020 period. The increase was primarily driven by an increase in corporate overhead costs of $2.6 million to support continued business growth, an increase in non-cash stock-based compensation of $1.3 million, one-time transaction-related expenses of $0.9 million, as well as recurring costs paid to third-party auditors and consultants related to our new status as a public company of $2.2 million, $1.6 million of which represents premiums for our directors’ and officers’ insurance. Excluding these one-time non-cash and recurring public company costs, G&A expense increased approximately $4.5 million to $6.6 million in the December 2021 quarter versus $2.1 million in the comparable 2020 period, primarily reflecting the continued expansion and enhancement of our corporate team as we execute on our growth plan, both organically and through acquisition. G&A remained roughly consistent on a percentage of revenues basis. Our software development expenses increased $0.5 million to $0.6 million in the December 2021 quarter, driven primarily by non-cash stock-based compensation of $0.3 million and an increased headcount of $0.2 million. Selling and marketing expenses increased one $1.1 million to $1.5 million in the December 2021 quarter, driven by our expansion of our Short Distance business lines and associated marketing activities. Compared to the pre-COVID comparable 2019 period, selling and marketing expenses increased $0.5 million or 49%, which primarily reflects increased marketing activities associated with our growth and business line expansion. Adjusted EBITDA in the December 2021 quarter decreased to -$5.9 million from -$1 million in the comparable 2020 period and -$4.6 million in the comparable 2019 period. The decrease was primarily attributable to increased headcount and new recurring expenses related to BLADE 's status as a public company consisting of incremental D&O insurance of $1.6 million and other fees paid to third-party auditors and consultants of 0.6 million excluding the new recurring public company expenses above comparable adjusted EBITDA of negative $3.7 million decreased versus negative $1 million in the comparable 2020 period, but improved from -$4.6 million. And the pre-COVID comparable 2019 period, driven by increased revenues and higher Flight Margin. Looking into the future, we're seeing an excellent start to the year. Even as we emerge from Omicron restrictions implemented late last year. As Rob mentioned earlier, we have seen a limited Omicron impact to our BLADE Airport and Vancouver businesses in the March 2022 quarter-to-date. Importantly, we are already seeing improvement across both businesses, and do not expect the material negative impact to revenues in the quarter. However, we do expect lower overall flight margins in the March 2022 quarter, likely in the low teens. Given our analysis to be impact of Omicron would be short-lived, we did not reduce service in order to maintain a consistent product offering for our customers. This led to lower utilization for BLADE Airport and in Vancouver. Fortunately, as we speak, mask mandates are being eliminated, travelers are booking more commercial flights, and workers are returning to the office in greater numbers. This bodes well for our performance in the immediate future. Looking more closely at BLADE Airport. While our annualized passenger run rate dropped to a low of approximately $5,000 in early January from approximately $20,000 in December, it has since doubled to approximately $10,000 in recent weeks. Note that January and February are seasonally weak months for commercial airline travel in general. Also within short distance, as the town of East Hampton, New York considers new flight restrictions at their airport, we expect a rebalancing of flier destinations to neighboring landing zones, including Montauk, South Hampton, Sag Harbor, and West Hampton. As these locations are as little as 10 minutes by car from the airport, we do expect a meaningful impact. However, even if the airport closed entirely, which we deem highly unlikely, BLADE expects only a low-to-mid single-digit million dollars revenue impact in calendar year 2022. This conservatively assumes that only half of our East Hampton Airport fliers would use one of the many other neighboring landing locations at a slightly increased price. In closing, I want to reiterate that despite these isolated issues, our growth remains incredibly strong. In fact, our January 20.2 revenues were roughly double the prior year period. With that, I'll turn it back over to Rob for a few closing remarks.